NCT02739568View on ClinicalTrials.gov

Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA

PHASE3CompletedINTERVENTIONAL
Enrollment

389

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Excessive Daytime SleepinessObstructive Sleep Apnea
Interventions
DRUG

Pitolisant (BF2.649)

DRUG

Placebo

Trial Locations (6)

1000

Hospital of Skopje, Skopje

1432

"University Multiprofile Hospital for Active Treatment Aleksandrovska EAD", Sofia

3320

"Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EOOD", Kozloduy

5000

"University Multiprofile Hospital for Active Treatment Kaspela EOOD Clinic of thoracic surgery", Plovdiv

5800

"Multiprofile Hospital for Active Treatment Sv. Paraskeva OOD", Pleven

8000

"Specialised Hospital for Active Treatment of pneumo-phthisiatric diseases - Burgas EOOD, Pneumology ward", Burgas

Sponsors

Lead Sponsor

Bioprojet
All Listed Sponsors
lead

Bioprojet

OTHER

NCT02739568 - Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA | Biotech Hunter | Biotech Hunter